Cargando…

Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center

Dupilumab is one of a number of biologics currently under investigation for the treatment of eosinophilic esophagitis (EoE). We report on a group of 7 pediatric and young adult patients with EoE who were treated with dupilumab for a primary indication of asthma or atopic dermatitis, all of whom prev...

Descripción completa

Detalles Bibliográficos
Autores principales: Syverson, Erin Phillips, Rubinstein, Eitan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158365/
https://www.ncbi.nlm.nih.gov/pubmed/37168913
http://dx.doi.org/10.1097/PG9.0000000000000180
_version_ 1785036913869062144
author Syverson, Erin Phillips
Rubinstein, Eitan
author_facet Syverson, Erin Phillips
Rubinstein, Eitan
author_sort Syverson, Erin Phillips
collection PubMed
description Dupilumab is one of a number of biologics currently under investigation for the treatment of eosinophilic esophagitis (EoE). We report on a group of 7 pediatric and young adult patients with EoE who were treated with dupilumab for a primary indication of asthma or atopic dermatitis, all of whom previously failed swallowed topical corticosteroid therapy dietary for management of their EoE. All 7 patients demonstrated histologic improvement in their EoE while on dupilumab, with a drop in median peak esophageal eosinophil count from 50 eosinophils per high-powered field (eos/hpf) (IQR 48–95 eos/hpf) to 2 eos/hpf (IQR 0–5 eos/hpf) off swallowed topical corticosteroid. Additionally, improvements in EoE symptoms and endoscopic findings were noted. This report highlights the effectiveness of dupilumab in a group of multiply atopic pediatric and young adult patients with difficult-to-treat EoE in real world practice.
format Online
Article
Text
id pubmed-10158365
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins, Inc.
record_format MEDLINE/PubMed
spelling pubmed-101583652023-05-09 Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center Syverson, Erin Phillips Rubinstein, Eitan JPGN Rep Brief Report Dupilumab is one of a number of biologics currently under investigation for the treatment of eosinophilic esophagitis (EoE). We report on a group of 7 pediatric and young adult patients with EoE who were treated with dupilumab for a primary indication of asthma or atopic dermatitis, all of whom previously failed swallowed topical corticosteroid therapy dietary for management of their EoE. All 7 patients demonstrated histologic improvement in their EoE while on dupilumab, with a drop in median peak esophageal eosinophil count from 50 eosinophils per high-powered field (eos/hpf) (IQR 48–95 eos/hpf) to 2 eos/hpf (IQR 0–5 eos/hpf) off swallowed topical corticosteroid. Additionally, improvements in EoE symptoms and endoscopic findings were noted. This report highlights the effectiveness of dupilumab in a group of multiply atopic pediatric and young adult patients with difficult-to-treat EoE in real world practice. Lippincott Williams & Wilkins, Inc. 2022-02-25 /pmc/articles/PMC10158365/ /pubmed/37168913 http://dx.doi.org/10.1097/PG9.0000000000000180 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Brief Report
Syverson, Erin Phillips
Rubinstein, Eitan
Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center
title Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center
title_full Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center
title_fullStr Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center
title_full_unstemmed Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center
title_short Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center
title_sort real world experience with dupilumab in eosinophilic esophagitis in children and young adults at a tertiary care pediatric medical center
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158365/
https://www.ncbi.nlm.nih.gov/pubmed/37168913
http://dx.doi.org/10.1097/PG9.0000000000000180
work_keys_str_mv AT syversonerinphillips realworldexperiencewithdupilumabineosinophilicesophagitisinchildrenandyoungadultsatatertiarycarepediatricmedicalcenter
AT rubinsteineitan realworldexperiencewithdupilumabineosinophilicesophagitisinchildrenandyoungadultsatatertiarycarepediatricmedicalcenter